These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 28432050

  • 1. Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus.
    Mok CC, Ho LY, Tse SM, Chan KL.
    Ann Rheum Dis; 2017 Aug; 76(8):1420-1425. PubMed ID: 28432050
    [Abstract] [Full Text] [Related]

  • 2. Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.
    Groot N, Shaikhani D, Teng YKO, de Leeuw K, Bijl M, Dolhain RJEM, Zirkzee E, Fritsch-Stork R, Bultink IEM, Kamphuis S.
    Arthritis Rheumatol; 2019 Feb; 71(2):290-301. PubMed ID: 30152151
    [Abstract] [Full Text] [Related]

  • 3. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
    Vázquez-Otero I, Medina-Cintrón N, Arroyo-Ávila M, González-Sepúlveda L, Vilá LM.
    Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission.
    Zen M, Saccon F, Gatto M, Montesso G, Larosa M, Benvenuti F, Iaccarino L, Doria A.
    Rheumatology (Oxford); 2020 Jul 01; 59(7):1591-1598. PubMed ID: 31642908
    [Abstract] [Full Text] [Related]

  • 6. Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations.
    Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K.
    Clin Rheumatol; 2019 Oct 01; 38(10):2785-2791. PubMed ID: 31175481
    [Abstract] [Full Text] [Related]

  • 7. A descriptive study of the factors associated with damage in Malaysian patients with lupus nephritis.
    Shaharir SS, Ghafor AH, Said MS, Kong NC.
    Lupus; 2014 Apr 01; 23(4):436-42. PubMed ID: 24399814
    [Abstract] [Full Text] [Related]

  • 8. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.
    Petri M, Magder LS.
    Arthritis Rheumatol; 2018 Nov 01; 70(11):1790-1795. PubMed ID: 29806142
    [Abstract] [Full Text] [Related]

  • 9. Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage.
    Floris A, Piga M, Perra D, Chessa E, Congia M, Mathieu A, Cauli A.
    Arthritis Care Res (Hoboken); 2020 Dec 01; 72(12):1794-1799. PubMed ID: 31600023
    [Abstract] [Full Text] [Related]

  • 10. Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis.
    Mok CC, Penn HJ, Chan KL, Tse SM, Langman LJ, Jannetto PJ.
    Arthritis Care Res (Hoboken); 2016 Sep 01; 68(9):1295-302. PubMed ID: 26749299
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease.
    Salgado Guerrero M, Londono Jimenez A, Dobrowolski C, Mowrey WB, Goilav B, Wang S, Broder A.
    BMC Nephrol; 2020 Oct 28; 21(1):450. PubMed ID: 33115441
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus.
    Akhavan PS, Su J, Lou W, Gladman DD, Urowitz MB, Fortin PR.
    J Rheumatol; 2013 Jun 28; 40(6):831-41. PubMed ID: 23588942
    [Abstract] [Full Text] [Related]

  • 16. Prolonged clinical remission and low disease activity statuses are associated with better quality of life in systemic lupus erythematosus.
    Poomsalood N, Narongroeknawin P, Chaiamnuay S, Asavatanabodee P, Pakchotanon R.
    Lupus; 2019 Sep 28; 28(10):1189-1196. PubMed ID: 31307256
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease.
    Iudici M, Pantano I, Fasano S, Pierro L, Charlier B, Pingeon M, Dal Piaz F, Filippelli A, Izzo V.
    Lupus; 2018 Feb 28; 27(2):265-272. PubMed ID: 28659047
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Risk of osteonecrosis in systemic lupus erythematosus: An 11-year Chinese single-center cohort study.
    Long Y, Zhang S, Zhao J, You H, Zhang L, Li J, Leng X, Wang Q, Tian X, Li M, Zeng X.
    Lupus; 2021 Aug 28; 30(9):1459-1468. PubMed ID: 34082592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.